Please login to the form below

bipolar disorder

This page shows the latest bipolar disorder news and features for those working in and with pharma, biotech and healthcare.

Sage raises $575m ahead of FDA review date for Zulresso

It also has an FDA breakthrough designation for this indication. The follow-up is also being developed in a phase 3 programme as a short oral course for major depressive disorder, ... It is also in earlier-stage studies for MDD plus insomnia as a

Latest news

Daily Brief: Italy in turmoil, Pharma attacks Europe's generics move and more

Its pipeline includes Risperidone Extended-Release Microspheres for Injection candidate (LY03004) for schizophrenia and bipolar disorder, and plans to launch in China and the US by the end of 2018, while
First digital medicine approved in the US

Abilify MyCite is the latest iteration of antipsychotic blockbuster Abilify (aripiprazole) to reach the market, and is approved for the same indications as its parent products - schizophrenia, bipolar I disorder and
Lundbeck and Otsuka start phase III for Rexulti in bipolar

Otsuka and co-development partner Lundbeck have started two phase III trials of their atypical antipsychotic Rexulti in bipolar disorder, potentially adding a third indication for the drug. ... Abilify. Lundbeck and Otsuka are also evaluating the drug in
Lundbeck partners with 23andMe on first-of-its-kind study

The US project will involve 25, 000 patients and combine data from genetics, cognitive tests and online surveys to explore how genetics is related to major depressive disorder (MDD), bipolar depression ... Anders Gersel Pedersen, executive VP, research
Otsuka refiles 'digital' medicine for mental illness

Abilify is approved to treat schizophrenia, bipolar disorder and major depressive disorder.

More from news
Approximately 7 fully matching, plus 81 partially matching documents found.

Latest Intelligence

Drug pricing in Ireland

As such, patients with coronary syndromes, multiple sclerosis, bipolar disorder and Hepatitis C were being denied access to effective treatments, while treatments for other diseases were also subject to restrictions.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

How health behaviours and clinical outcomes are related

Patients suffering from post-traumatic stress disorder, schizophrenia, bipolar disorder and depression also have more positive outcomes with higher patient activation levels. .
AN ADVOCACY Rx FOR PROGRESS IN MENTAL HEALTH

there’s an abundance of smart thinking on how to improve the lives of people who struggle with major depression, schizophrenia, bipolar disorder, and other serious conditions.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Head of Partnerships - Competitive - London: Competitive Salary Offered

Midweight Brand Planner: Up to £50, 000

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Senior / Principal Medical Writer / ETL - MedComms - HOME BASED ...: D.O.E

Senior Medical Writer: Salary TBC

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Subscribe to our email news alerts

PMHub

Add my company

Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Playing Mind Games: To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists: P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future: As I sit here at another pharma conference, I start to reflect on how they have changed over the years....